Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 13, 2025 16:05 ET | Source: Alumis Inc.

Alumis Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Alumis Reports Second Quarter 2025 Financial Results and Provides Corporate Update
July 14, 2025 16:05 ET | Source: Alumis Inc.

Alumis Announces the Promotion of Sanam Pangali to Chief Legal Officer and Corporate Secretary

Alumis Announces the Promotion of Sanam Pangali to Chief Legal Officer and Corporate Secretary
May 14, 2025 16:05 ET | Source: Alumis Inc.

Alumis Reports First Quarter 2025 Financial Results and Highlights Recent Achievements

Alumis Reports First Quarter 2025 Financial Results and Highlights Recent Achievements
May 13, 2025 13:00 ET | Source: Alumis Inc.

Alumis Stockholders Approve Merger with ACELYRIN

Alumis Stockholders Approve Merger with ACELYRIN
March 19, 2025 16:05 ET | Source: Alumis Inc.

Alumis Reports Year End 2024 Financial Results and Highlights Recent Achievements

Alumis Reports Year End 2024 Financial Results and Highlights Recent Achievements
March 10, 2025 08:00 ET | Source: Alumis Inc.

Alumis to Present at Leerink's 2025 Global Healthcare Conference

Alumis to Present at Leerink's 2025 Global Healthcare Conference
February 27, 2025 16:15 ET | Source: Alumis Inc.

Alumis Presents Additional Phase 1 Data at ACTRIMS Forum 2025 Supporting Potential of A-005 as First-in-Class CNS Penetrant TYK2 Inhibitor for Treatment of Neuroinflammatory and Neurodegenerative Diseases

Phase 1 Data at ACTRIMS Forum 2025 supports potential of A-005 as first-in-class CNS-penetrant TYK2 Inhibitor for neuroinflammatory diseases
February 10, 2025 16:45 ET | Source: Alumis Inc.

Alumis to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

Alumis to present at Oppenheimer 35th Annual Healthcare Life Sciences Conference on Tuesday, February 11, 2025 at 3:20 pm ET.
February 06, 2025 16:15 ET | Source: Alumis Inc.

Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases

Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Company Developing and Commercializing Transformative Therapies for Immune-mediated Diseases
January 28, 2025 08:00 ET | Source: Alumis Inc.

Alumis Strengthens Leadership Team with Key Appointments

Alumis has strengthened its leadership team with CCO and CLO to support its transition to a late-stage company.